INT126498

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.41
First Reported 2005
Last Reported 2010
Negated 1
Speculated 2
Reported most in Body
Documents 2
Total Number 4
Disease Relevance 1.21
Pain Relevance 2.64

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

oxidoreductase activity (Cyp1a2) endoplasmic reticulum (Cyp1a2) enzyme binding (Cyp1a2)
response to stress (Cyp1a2)
Cyp1a2 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
lidocaine 24 100.00 Very High Very High Very High
antidepressant 7 99.72 Very High Very High Very High
fluoxetine 11 99.24 Very High Very High Very High
sSRI 56 89.48 High High
antagonist 46 81.88 Quite High
headache 6 70.92 Quite High
tricyclic antidepressant 3 60.80 Quite High
Serotonin 18 33.52 Quite Low
dexamethasone 10 5.00 Very Low Very Low Very Low
Opioid 8 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Toxicity 3 99.08 Very High Very High Very High
Pressure Volume 2 Under Development 2 94.28 High High
Hypersensitivity 1 72.40 Quite High
Headache 6 70.92 Quite High
Vomiting 112 66.88 Quite High
Convulsion 4 65.56 Quite High
Anxiety Disorder 88 63.04 Quite High
Dizziness 2 62.28 Quite High
Constipation 4 61.52 Quite High
Overdose 3 56.36 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces elimination of lidocaine and may increase the risk of lidocaine toxicity.
Spec (may) Positive_regulation (increase) of Negative_regulation (inhibition) of CYP1A2 associated with toxicity and lidocaine
1) Confidence 0.41 Published 2005 Journal Anesth. Analg. Section Abstract Doc Link 15845683 Disease Relevance 0.10 Pain Relevance 0.93
We conclude that inhibition of CYP1A2 by fluvoxamine considerably reduces the presystemic metabolism of oral lidocaine and may increase the risk of lidocaine toxicity if lidocaine is ingested.
Spec (may) Positive_regulation (increase) of Negative_regulation (inhibition) of CYP1A2 associated with toxicity and lidocaine
2) Confidence 0.24 Published 2006 Journal Basic Clin. Pharmacol. Toxicol. Section Abstract Doc Link 16918719 Disease Relevance 0.10 Pain Relevance 0.96
Palonosetron does not cause inhibition or induction of the main hepatic enzyme systems including CYP2D6, CYP1A2 and CYP3A4/5, so the risk of significant drug interactions is low.119 However an adverse reaction with apomorphine that presented as profound hypotension and altered consciousness has been reported, so concomitant use is contraindicated.128


Neg (not) Positive_regulation (cause) of Negative_regulation (inhibition) of CYP1A2 associated with pressure volume 2 under development
3) Confidence 0.06 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2697527 Disease Relevance 0.77 Pain Relevance 0.20
Some antidepressants are not only substrates for CYP450 metabolism, but are also inhibitors of the metabolic clearance of other drugs, sometimes producing clinically significant drug-drug interactions.32 Fluvoxamine is a potent inhibitor of CYP1A2 and CYP2C9, while fluoxetine and paroxetine potently inhibit CYP2D6.
Positive_regulation (substrates) of Negative_regulation (inhibitor) of CYP1A2 associated with antidepressant and fluoxetine
4) Confidence 0.06 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877605 Disease Relevance 0.24 Pain Relevance 0.54

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox